Found: 3
Select item for more details and to access through your institution.
ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast Cancer.
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 3, p. 903, doi. 10.3390/ijms21030903
- By:
- Publication type:
- Article
CDH22 hypermethylation is an independent prognostic biomarker in breast cancer.
- Published in:
- Clinical Epigenetics, 2017, v. 9, p. 1, doi. 10.1186/s13148-016-0309-z
- By:
- Publication type:
- Article
A DNA Methylation-Based Gene Signature Can Predict Triple-Negative Breast Cancer Diagnosis.
- Published in:
- Biomedicines, 2021, v. 9, n. 10, p. 1394, doi. 10.3390/biomedicines9101394
- By:
- Publication type:
- Article